Sage Therapeutics, Inc.
SAGE
|
$13.35
2.42%
2.36%
1.3M
|
Health Technology
(0.0% 1d) (-36.1% 1m) (-73.1% 1y) (0.0% 2d) (0.0% 3d) (-18.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 802,424,271
http://www.sagerx.com
Sec Filling | Patents | 675 employees
(US) SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
depression nervous system treatment
Drugs
Zulresso (brexanolone)add to watch list Paper trade email alert is off
Press-releases
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 2.37%
H: 0.9%
C: -0.54%
first report therapeutics financial results
Sage Therapeutics to Present at Upcoming March Investor Conferences
Published: 2024-02-28 (Crawled : 13:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -0.48%
H: 0.71%
C: -0.22%
therapeutics
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 9.69%
H: 8.48%
C: 1.98%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
business year pipeline therapeutics financial results
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
Published: 2024-01-31 (Crawled : 22:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -0.12%
H: 2.82%
C: -0.89%
report year therapeutics financial results
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
Published: 2024-01-02 (Crawled : 13:30) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -1.48%
H: 7.03%
C: 5.29%
conference therapeutics
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 3.04%
H: 0.0%
C: -3.59%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.56%
H: 1.74%
C: -0.18%
depression treatment women
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
Published: 2023-10-24 (Crawled : 11:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 1.52%
H: 4.69%
C: 2.47%
report therapeutics financial results
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
Published: 2023-10-18 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: 0.87%
H: 1.61%
C: -3.0%
sage-718 drug disease granted food treatment designation therapeutics
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
Published: 2023-08-31 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -0.25%
H: 3.97%
C: 1.68%
pipeline commercial therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 1070000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT | News P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
22:00
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10